Clobazam: Effect on Frequency of Seizures and Safety Profile in Different Subgroups of Children With Epilepsy

Imagem de Miniatura
Arquivos
art_KLEHM_Clobazam_Effect_on_Frequency_of_Seizures_and_Safety_2014.PDF (239.67 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2014
Editora
ELSEVIER SCIENCE INC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
KLEHM, Jacquelyn
FERNANDEZ, Ivan Sanchez
BERGIN, Ann M.
BOLTON, Jeffrey
HARINI, Chellamani
KADISH, Navah E.
LIBENSON, Mark
PETERS, Jurriaan
PODURI, Annapurna
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PEDIATRIC NEUROLOGY, v.51, n.1, p.60-66, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND: Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes. We evaluated the efficacy and safety of clobazam in a large sample of patients with refractory epilepsy at a tertiary pediatric center. METHODS: We retrospectively reviewed patients treated with clobazam between January 2001 and July 2013 who had a follow-up visit at least one month after starting clobazam. Response was defined as >= 50% reduction in seizure frequency compared with baseline seizure frequency during the 3 months before the introduction of clobazam. We examined the relationship between dose range and response rate. RESULTS: Four-hundred twenty-five patients were prescribed clobazam, of whom 300 (median age 9.1 years, interquartile range 4.7-13.3 years) had follow-up data greater than 1 month. Median follow-up was 5 months (interquartile range 3-11 months). Response to treatment with clobazam was observed in 203 of 300 (67.7%) patients, of whom 84 (28%) became seizure-free. The median starting dose was 0.2 (interquartile range 0.13-0.33) mg/kg/day with a target dose of 0.48 (0.26-0.80) mg/kg/day. Twenty-seven (9%) patients discontinued clobazam, 16 (59.3%) because adverse effects, 10 (37%) because of a lack of efficacy, and one (3.7%) because of a combination of adverse effects and lack of efficacy. The most common adverse effects were tiredness in 44 of 300 (14.6%) and mood or behavioral changes in 23 (7.7%). CONCLUSIONS: Clobazam is a well-tolerated antiepileptic drug with good response rates in pediatric patients with refractory epilepsy.
Palavras-chave
epilepsy, refractory epilepsy, pediatric, seizure, efficacy
URI
https://observatorio.fm.usp.br/handle/OPI/7894
Referências
  1. ALLEN JW, 1983, BRIT MED J, V286, P1246
  2. Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x
  3. Bond AJ, 1998, CNS DRUGS, V9, P41, DOI 10.2165/00023210-199809010-00005
  4. BUCHANAN N, 1993, J ROY SOC MED, V86, P378
  5. Booth F, 1998, EPILEPSIA, V39, P952
  6. Conry JA, 2009, EPILEPSIA, V50, P1158, DOI 10.1111/j.1528-1167.2008.01935.x
  7. Corman C, 1998, SEIZURE-EUR J EPILEP, V7, P243, DOI 10.1016/S1059-1311(98)80043-5
  8. da Silveira MRM, 2006, ARQ NEURO-PSIQUIAT, V64, P705, DOI 10.1590/S0004-282X2006000500001
  9. FARRELL K, 1986, EPILEPSIA, V27, pS45, DOI 10.1111/j.1528-1157.1986.tb05733.x
  10. GASTAUT H, 1979, EPILEPSIA, V20, P437, DOI 10.1111/j.1528-1157.1979.tb04825.x
  11. Higuchi T, 2011, EPILEPTIC DISORD, V13, P166, DOI 10.1684/epd.2011.0423
  12. Jan MM, 2000, SAUDI MED J, V21, P622
  13. Jennesson M, 2013, EPILEPSY RES, V104, P269, DOI 10.1016/j.eplepsyres.2012.10.010
  14. Kalra V, 2010, INDIAN J PEDIATR, V77, P263, DOI 10.1007/s12098-010-0035-z
  15. KEENE DL, 1990, CAN J NEUROL SCI, V17, P317
  16. Khosroshahi N, 2011, INDIAN J PEDIATR, V78, P38, DOI 10.1007/s12098-010-0220-0
  17. Leahy JT, 2011, NEUROPSYCH DIS TREAT, V7, P673, DOI [10.2147/NDT.S20173, 10.2147/NDT.520173]
  18. Lee EH, 2013, CLIN NEUROPHARMACOL, V36, P4, DOI 10.1097/WNF.0b013e3182770730
  19. McKenzie WS, 2010, J ORAL MAXIL SURG, V68, P3034, DOI 10.1016/j.joms.2010.06.176
  20. Mehndiratta MM, 2003, SEIZURE-EUR J EPILEP, V12, P226, DOI 10.1016/S1059-1311(02)00263-7
  21. Michael B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004154.pub4
  22. Mills JKA, 2011, SEIZURE-EUR J EPILEP, V20, P402, DOI 10.1016/j.seizure.2011.01.011
  23. Montenegro MA, 2001, EPILEPSIA, V42, P539, DOI 10.1046/j.1528-1157.2001.31600.x
  24. Montenegro MA, 2008, CLIN NEUROPHARMACOL, V31, P333, DOI [10.1097/WNF.0b013e31815cd960, 10.1097/WNF.0B013E31815CD960]
  25. MUNN R, 1993, PEDIATR NEUROL, V9, P465, DOI 10.1016/0887-8994(93)90026-9
  26. Ng YT, 2012, EPILEPSY BEHAV, V25, P687, DOI 10.1016/j.yebeh.2012.09.039
  27. Ng YT, 2011, NEUROLOGY, V77, P1473, DOI 10.1212/WNL.0b013e318232de76
  28. Ng YT, 2007, NEUROTHERAPEUTICS, V4, P138, DOI 10.1016/j.nurt.2006.11.002
  29. Paton C, 2002, PSYCHIAT B, V26, P460, DOI 10.1192/pb.26.12.460
  30. Perry MS, 2013, J CHILD NEUROL, V28, P34, DOI 10.1177/0883073812461943
  31. Rose Winsley, 2005, Indian Journal of Pediatrics, V72, P31, DOI 10.1007/BF02760577
  32. Sankar R, 2012, CNS DRUGS, V26, P229, DOI 10.2165/11599020-000000000-00000
  33. SCHMIDT D, 1986, ARCH NEUROL-CHICAGO, V43, P824
  34. SHETH RD, 1995, J CHILD NEUROL, V10, P205
  35. SHIMIZU H, 1982, BRAIN DEV-JPN, V4, P57
  36. Silva RC, 2006, CAN J NEUROL SCI, V33, P209
  37. Stewart WA, 2002, J CHILD NEUROL, V17, P154
  38. Vajda F J, 1985, Clin Exp Neurol, V21, P177
  39. Wheless JW, 2013, J CHILD NEUROL, V28, P219, DOI 10.1177/0883073812463609

Coleções
Artigos e Materiais de Revistas Científicas - LIM/21